Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Olaparib is a poly (ADP-ribose) polymerase inhibitor used in BRCA-mutated cancers.
• Carbonyl-reducing enzymes (CREs) are implicated in cancer cell resistance to anthracyclines like daunorubicin.
• Understanding drug metabolism interactions is crucial for optimizing cancer therapy.

Purpose of the Study:

• To investigate olaparib's interference with daunorubicin metabolism mediated by CREs.
• To explore the potential of this interaction for overcoming anthracycline resistance.

Main Methods:

• In vitro incubation experiments with recombinant CREs.
• Enzyme inhibition assays using AKR1C3-overexpressing HCT116 cells.
• Molecular docking studies to elucidate interaction mechanisms.
• Drug combination experiments in various cancer cell lines (HCT116, HepG2, KG1α).
• Analysis of AKR1C3 mRNA expression.

Main Results:

• Olaparib was identified as a potent inhibitor of aldo-keto reductase 1C3 (AKR1C3).
• Olaparib demonstrated significant intracellular inhibition of AKR1C3 in transfected HCT116 cells.
• Molecular docking supported the interaction between olaparib and AKR1C3.
• Drug combination studies revealed a synergistic enhancement of daunorubicin's antiproliferative effect.
• Olaparib did not significantly affect AKR1C3 mRNA expression in HepG2 and KG1α cells.

Conclusions:

• Olaparib interferes with anthracycline metabolism by inhibiting AKR1C3.
• This interaction can be leveraged to enhance the efficacy of daunorubicin.
• The findings suggest a potential strategy for overcoming anthracycline resistance in cancer treatment.